{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:57:57Z","timestamp":1753891077204,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have become a standard treatment for various cancers, but their use is often associated with immune-related adverse events (irAEs), including cutaneous irAEs (cirAEs). Here, we report a rare case of subacute cutaneous lupus erythematosus (SCLE) induced by sintilimab, a PD-1 inhibitor, in a 30-year-old woman undergoing neoadjuvant chemo-immunotherapy for gastric cancer. The patient presented with erythema, macules, papules, and vesicles, with positive ANA (108U\/mL) and strongly positive anti-SSA\/Ro. After discontinuation of sintilimab and treatment with corticosteroids, hydroxychloroquine, and intravenous immunoglobulin (IVIG), her symptoms improved. This case represents the first reported instance of drug-induced lupus caused by sintilimab and emphasizes the importance of distinguishing between paraneoplastic lupus and ICI-induced lupus.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1544312","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T05:24:42Z","timestamp":1745472282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Subacute cutaneous lupus erythematosus triggered by sintilimab: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Chenxi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiali","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune checkpoint inhibitors: A dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020252","article-title":"Immune checkpoint inhibitors and lupus erythematosus","volume":"17","author":"Vitzthum von Eckstaedt","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19918","article-title":"Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial","volume":"330","author":"Xu","year":"2023","journal-title":"JAMA"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13030\/qt3nw0p7hn","DOI":"10.5070\/D32511046136","article-title":"Systemic 5-fluorouracil induced lupus erythematosus: a review of the literature","volume":"25","author":"Shakhbazova","year":"2019","journal-title":"Dermatol Online J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.025","article-title":"PD-1 immunobiology in systemic lupus erythematosus","volume":"97","author":"Curran","year":"2019","journal-title":"J Autoimmun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00265","article-title":"Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment","volume":"5","author":"Celhar","year":"2014","journal-title":"Front Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol","article-title":"Type I interferon in the pathogenesis of lupus","volume":"192","author":"Crow","year":"2014","journal-title":"J Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2022.09.005","article-title":"Cutaneous lupus erythematosus: a review of etiopathogenic, clinical, diagnostic and therapeutic aspects","volume":"98","author":"Vale","year":"2023","journal-title":"Bras Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2022.07.007","article-title":"Subacute cutaneous lupus erythematosus: A facultative paraneoplastic dermatosis","volume":"40","author":"Lazar","year":"2022","journal-title":"Clin Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/0961203309106176","article-title":"Drug-induced lupus: an update on its dermatologic aspects","volume":"18","author":"Marzano","year":"2009","journal-title":"Lupus"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544312\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T05:24:43Z","timestamp":1745472283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1544312\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2025.1544312"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1544312","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"article-number":"1544312"}}